Amgen Inc. $AMGN Stock Holdings Boosted by Allianz SE

Allianz SE increased its position in Amgen Inc. (NASDAQ:AMGN) by 7.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 41,346 shares of the medical research company’s stock after acquiring an additional 3,040 shares during the period. Allianz SE’s holdings in Amgen were worth $11,668,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Legacy Investment Solutions LLC acquired a new position in shares of Amgen during the second quarter worth approximately $27,000. Evelyn Partners Investment Management LLP bought a new stake in Amgen during the 2nd quarter valued at $32,000. Howard Hughes Medical Institute acquired a new position in Amgen during the 2nd quarter worth $32,000. Cloud Capital Management LLC bought a new position in shares of Amgen in the third quarter worth $34,000. Finally, Nvwm LLC increased its holdings in shares of Amgen by 893.3% during the second quarter. Nvwm LLC now owns 149 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 134 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported a new evolocumab bioavailability study that refines dosing/PK assessment for its PCSK9 cholesterol franchise, signaling management’s continued investment in a long‑lived cardiovascular product line and potential lifecycle optimization. Amgen Fine-Tunes Evolocumab
• Positive Sentiment: Amgen advanced maridebart (cafraglutide) toward a Phase 2b obesity and liver‑fat trial — news that expands the company’s obesity pipeline and supports upside potential beyond core biologics. Pipeline progress tends to lift pharma multiples. Amgen Advances Maridebart
• Positive Sentiment: Coverage and momentum narratives are supportive — Zacks highlights AMGN as a top long‑term momentum stock, which can attract trend‑driven and fund flows. Why Amgen is a Top Momentum Stock
• Positive Sentiment: Market headlines note AMGN reaching an all‑time high and outperforming the Dow recently — reinforcement for bullish sentiment and potential technical buying. Amgen stock hits all-time high Is Amgen Stock Outperforming the Dow?
• Neutral Sentiment: Biotech sector activity: a large biotech IPO (Generate Biomedicines) indicates healthy capital markets for life sciences, which can be a neutral tailwind for large biotech names but doesn’t directly change Amgen’s fundamentals. Generate caps a strong month for biotech IPOs
• Neutral Sentiment: Minor portfolio rebalancing: a small sale by Bradley Foster & Sargent reduced a modest position in AMGN — not material to shares outstanding or sentiment. Bradley Foster & Sargent sells AMGN
• Negative Sentiment: Policy risk: a proposed U.S. bill to tighten rules on corporate inversions mentions AMGN among companies potentially affected by changes to international tax treatment — could raise longer‑term tax/structural uncertainty if enacted. Impact is uncertain and likely small near term. Stop Corporate Inversions Act of 2026
• Neutral Sentiment: Reported short‑interest data in feeds looks inconsistent (zeros/NaN) and should be treated with caution; no clear signal from short interest trends. (data sources above).

Wall Street Analyst Weigh In

Several research firms recently weighed in on AMGN. Leerink Partners upped their price objective on shares of Amgen from $305.00 to $355.00 and gave the stock an “outperform” rating in a report on Wednesday, February 4th. Erste Group Bank upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Daiwa Securities Group upped their target price on Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $351.76.

Amgen Stock Up 2.3%

Shares of NASDAQ:AMGN opened at $388.16 on Friday. The company has a market cap of $209.25 billion, a PE ratio of 27.28, a price-to-earnings-growth ratio of 3.76 and a beta of 0.46. The firm has a 50 day simple moving average of $348.89 and a 200 day simple moving average of $319.48. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $390.14.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.6%. This is an increase from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio is presently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.